Gri Bio Operations, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2009-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.gribio.com
Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients with IPF
Phase 2
Recruiting
- Conditions
- Idiopathic Pulmonary FibrosisIPF
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- GRI Bio Operations, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06331624
- Locations
- 🇺🇸
Newport Native MD, Inc., Newport Beach, California, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease
Phase 2
Terminated
- Conditions
- Chronic Liver Disease
- Interventions
- Drug: Placebo Comparator
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- GRI Bio Operations, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02949375
- Locations
- 🇿🇦
Steve Biko Academic Hospital, Pretoria, Gauteng, South Africa
© Copyright 2025. All Rights Reserved by MedPath